Imatinib Basics (Imatinib)

Imatinib targets specific tyrosine‑kinase driven cancers and is employed in several approved indications.

• Chronic myeloid leukemia: provides targeted inhibition of BCR‑ABL, improving hematologic and cytogenetic response.
• Gastrointestinal stromal tumor: blocks c‑KIT signaling, reducing tumor growth and recurrence.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: offers a molecularly directed therapy that enhances remission rates.

• Imatinib binds competitively to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition halts proliferative signaling pathways, induces apoptosis, and limits angiogenesis in malignant cells that depend on these kinases for growth and survival.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the hands, feet, or periorbital area.
• Fatigue: persistent tiredness not relieved by rest.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury.
• Cardiac failure: signs of reduced heart function such as dyspnea.
• Severe bleeding: gastrointestinal or intracranial hemorrhage requiring urgent care.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

• Blood count monitoring: perform complete blood counts weekly for the first month, then periodically.
• Liver function assessment: check ALT/AST levels before treatment and during therapy.
• Cardiac evaluation: obtain baseline ECG in patients with known heart disease.
• Hypersensitivity avoidance: discontinue if severe rash or anaphylaxis occurs.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several concomitant medications, requiring dose adjustments or close observation.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic exposure.
• Proton pump inhibitors: can lower absorption, potentially diminishing efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR more frequently due to altered anticoagulant effect.
• Digoxin: assess serum levels as imatinib may affect renal clearance.